A tale of two antiviral targets — and the COVID-19 drugs that bind them

A tale of two antiviral targets — and the COVID-19 drugs that bind them

Beyond Omicron: what’s next for COVID’s viral evolution

Beyond Omicron: what’s next for COVID’s viral evolution

25 Years of the Office of Cancer Survivorship | Former DCCPS Director, D...

25 Years of Survivorship Science | Office of Cancer Survivorship Directo...

Diverse genome sequences provide a powerful tool for studying risk of heart disease | National Institutes of Health (NIH)

Diverse genome sequences provide a powerful tool for studying risk of heart disease | National Institutes of Health (NIH)

Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC) Public Workshop - 01/24/2022 - 01/25/2022 | FDA

Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC) Public Workshop - 01/24/2022 - 01/25/2022 | FDA

Breast Cancer Risk Model | Risk Researchers | Childhood Cancer Drivers, Cancer Information Highlights, 12/08/2021

Breast Cancer Risk Model | Risk Researchers | Childhood Cancer Drivers, Cancer Information Highlights, 12/08/2021